tbuckley/cabot-search huggingface dataset:
PWE-026 Multiple Polyps Have A Higher Predictive Value For Positive Findings On Surveillance Colonoscopy Than Fewer Large Lesions: Abstract PWE-026 Table 1
Authors: A Kamora, K Kandiah, G Smith, J Martin
Journal: Gut (2014)

<h3>Introduction</h3> Individuals with adenomatous polyps are at increased risk of developing further neoplasia and it is recommended that these individuals undergo colonoscopic surveillance at an interval dictated by the size of the adenoma and/or the number of adenomas removed. This study documents the findings at surveillance colonoscopies in individuals within the Bowel Cancer Screening Programme (BCSP). <h3>Methods</h3> All patients undergoing surveillance colonoscopies within the BCSP at West London Bowel Cancer Screening Centre (WLBCS) between 1<sup>st</sup> January 2009 and 1<sup>st</sup> February 2013 were were stratified into four groups according to the findings at the index colonoscopy as follows: Group A – 3 or more adenomas with at least one = 10 mm Group B – 5 or more small adenomas all &lt;10 mm Group C – 1 or 2 adenomas = 10 mm Group D – 3 or 4 small adenomas all &lt;10 mm The percentage of adenomas found at surveillance colonoscopy in patients with few adenomas at index colonoscopy was compared to adenoma yield in patients with multiple adenomas at index colonoscopy using Fishers exact test. <h3>Results</h3> 242 patients underwent colonoscopies within the study period and a total of 379 adenomas were found in 145 patients. 19 adenomas were greater than 10mm (5.0%) and 3 adenomas showed high grade dysplasia (0.8%). The percentage of patients with adenomas found within the groups A-D is shown in the table below. Overall the percentage of patients with adenomas was 69.0% in those patients having their surveillance procedure at 1 year and 47.0% in those individuals having their colonoscopy at 3 years. For both surveillance intervals, the group with the largest number of adenomas found at the index procedure had a higher adenoma yield during surveillance. Overall, adenomas were found in 67.8% of patients with multiple adenomas found at the index colonoscopy (groups A, B, D) and in 43.6% of patients with 1 or 2 larger lesions (group C) (p = 0.0004). <h3>Conclusion</h3> Adenoma detection at surveillance colonoscopy within the BCSP is high, at both the 1 year and the 3 year interval, suggesting that this is a valuable intervention in reducing future risk of colorectal cancer. The yield of high-risk lesions of a large size or with high-grade dysplasia, however, is low. The yield of adenoma detection is higher in individuals undergoing surveillance for high numbers of diminutive lesions compared to those individuals with 1 or 2 large adenomas. This finding may reflect the presence of a generalised colonic field effect in those individuals with multiple lesions, compared to a more local abnormality in those with small numbers of lesions. <h3>Disclosure of Interest</h3> None Declared.
Image-guided, intensity-modulated radiation therapy (IG-IMRT) for skull base chordoma and chondrosarcoma: preliminary outcomes
Authors: A. Sahgal, M. W. Chan, E. G. Atenafu, L. Masson-Cote, G. Bahl, E. Yu, B.-A. Millar, C. Chung, C. Catton, B. O'Sullivan, J. C. Irish, R. Gilbert, G. Zadeh, M. Cusimano, F. Gentili, N. J. Laperriere
Journal: Neuro-Oncology (2014)

We report our preliminary outcomes following high-dose image-guided intensity modulated radiotherapy (IG-IMRT) for skull base chordoma and chondrosarcoma.Forty-two consecutive IG-IMRT patients, with either skull base chordoma (n = 24) or chondrosarcoma (n = 18) treated between August 2001 and December 2012 were reviewed. The median follow-up was 36 months (range, 3-90 mo) in the chordoma cohort, and 67 months (range, 15-125) in the chondrosarcoma cohort. Initial surgery included biopsy (7% of patients), subtotal resection (57% of patients), and gross total resection (36% of patients). The median IG-IMRT total doses in the chondrosarcoma and chordoma cohorts were 70 Gy and 76 Gy, respectively, delivered with 2 Gy/fraction.For the chordoma and chondrosarcoma cohorts, the 5-year overall survival and local control rates were 85.6% and 65.3%, and 87.8% and 88.1%, respectively. In total, 10 patients progressed locally: 8 were chordoma patients and 2 chondrosarcoma patients. Both chondrosarcoma failures were in higher-grade tumors (grades 2 and 3). None of the 8 patients with grade 1 chondrosarcoma failed, with a median follow-up of 77 months (range, 34-125). There were 8 radiation-induced late effects-the most significant was a radiation-induced secondary malignancy occurring 6.7 years following IG-IMRT. Gross total resection and age were predictors of local control in the chordoma and chondrosarcoma patients, respectively.We report favorable survival, local control and adverse event rates following high dose IG-IMRT. Further follow-up is needed to confirm long-term efficacy.
FRI0306 Favorable Effects of Rituximab Treatment on Lipid Profile, Arterial Stiffness, Carotid Atherosclerosis and Silent Myocardial Ischemia in Women with Rheumatoid Arthritis: Table 1
Authors: D.S. Novikova, T.V. Popkova, E.V. Gerasimova, E.I. Markelova, A.V. Volkov, O.A. Fomicheva, A.A. Novikov, E.N. Alexandrova, D.E. Karateev, E.L. Nasonov
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> To study whether rituximab (RTX) modifies lipid profile, systolic (SBP) and diastolic (DBP) blood pressure, body mass index (BMI), blood glucose level, arterial stiffness (AS), carotid intima-media thickness (cIMT) and the frequency of silent myocardial ischemia (SMI) in women with RA without overt cardiovascular disease (CVD). <h3>Methods</h3> 55 women with RA were observed, during this study we determined plasma total cholesterol (TC), HDL-C, LDL-C, and triglyceride (TG) levels, AS (SI - stiffness index, RI – reflection index and frequency of patients (pt) with "stiff arteries") by digital volume pulse contour analysis (Micro Medical, UK), performed high resolution B-mode carotid ultrasound with measurement of cIMT. Episodes of SMI were investigated by 24 h ECG ambulatory recording. Assessments were performed before and 24 weeks after RTX therapy (2 infusions of 500/1000 mg RTX iv. 14 days apart). Index activity (DAS 28), inflammatory markers (CRP, ESR), RF IgM in serum were measured in all pt. <h3>Results</h3> We divided pt into 2 groups: 1 - moderate/good effect (EULAR) of RTX therapy after 24 weeks (41 pt, 75%), 2 - without EULAR effect of RTX therapy after 24 weeks (14 pt, 25%), table 1. Effective RTX therapy resulted in 5% increase in TC, 23% increase in HDL-C as well as 14% decrease in atherogenic index (AI). RTX treatment also resulted in a dramatically decrease in stiffness index (57%), reflection index (24%) and frequency of patients with "stiff arteries" (from 52% to 15%). We observed 9% decreases in cIMTmax at weeks 24. The frequency of SMI was significantly lower after 24 week when before RTX therapy in group 1 (table 1). The improvement of cardiovascular parameters was associated with a significant decrease in CRP level, ESR, RF IgM and DAS 28 in group 1 (p&lt;0,05). There were not significant changes of lipid profile, AS, cIMT and the frequency of SMI in group 2. We also didn9t find differences in SBP, DBP, BMI and blood glucose level in group 1 and 2 before and 24 weeks after RTX therapy. <h3>Conclusions</h3> Two infusions of RTX in case of moderate/good EULAR effect of therapy exerted favorable effects on lipid profile, arterial stiffness, carotid atherosclerosis and silent myocardial ischemia in women with RA without overt CVD. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1795
AB0678 Artrhitic patterns in systemic lupus erythematosus
Authors: J.G. Ovalles-Bonilla, J. Martínez-Barrio, F. Lόpez-Longo, I. de la Torre, C. González, L. Valor, M. Montoro-Άlvarez, F. Aramburu, C. Marín, L. Martínez-Estupiñán, J. Nieto, M. Hinojosa, N. Bello, I. Monteagudo, L. Carreño
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To describe the arthritic patterns in Systemic Lupus Erythematosus (SLE) patients and their relationship with clinical and immunological features. <h3>Methods</h3> Data was obtained from a long term prospective cohort of SLE patients recruited between 1986 and 2010 in the Rheumatology Department of Gregorio Marañon Hospital in Madrid, Spain. Demographic, clinical, and laboratory data were collected at disease onset and during it’s course. Patients were divided into 4 groups according to arthritic pattern: acute oligoarthritis, chronic oligoarthritis, acute polyarthritis and chronic polyarthritis. Organ damage was scored using the SLICC/ACR Damage Index. <h3>Results</h3> A total of 522 patients were included, of whom 465 were women. Arthritis was present at diagnosis in 29.7% of patients. The chronic variants (oligo and poly) presented more frequently in association with Sjögren syndrome. Other manifestations like bony erosions, hypogammaglobulinemia and osteoporosis were considerably more frequent in the chronic polyarthritis group. A higher frequency of renal manifestations was observed in the acute arthritis groups, both at disease onset and during evolution. During the follow-up period 68.4% of patients developed arthritis. The chronic polyarthritis group shows a statistically significant association with morning stiffness, bony erosions, Sjögren syndrome, Jaccoud’s arthropathy, osteoporosis, hypogammaglobulinemia, orthopedic interventions, drug side effects and higher serum levels of rheumatoid factor. A trend towards higher titers of ACPA and anti-modified citrullinated vimentin was also seen in the chronic polyarthritis group, although the differences among groups did not reach statistical significance. Mortality, damage accrual, and systemic manifestations are not related to any arthritic pattern in particular. <h3>Conclusions</h3> At disease onset 30% of patients presented with arthritis, and 70% of all studied patients developed some kind of arthritic pattern during the course of the disease. Renal manifestations are related to acute oligo and polyarthritis. Damage accrual, systemic manifestations and mortality are not associated with any particular arthritic pattern. <h3>Disclosure of Interest</h3> None Declared
PTH-068 The use of Oesophageal Capsule Endoscopy in Patients with Haemophilia; Experience from a Tertiary Centre
Authors: Y L Ang, A Koulaouzidis, S Douglas, J N Plevris
Journal: Gut (2013)

<h3>Introduction</h3> A great proportion of haemophiliacs are considered at risk of being co-infected with hepatitis C (HCV) and variant Creutzfeldt-Jakob Disease (vCJD). <sup>1</sup> Chronic hepatitis C leads to liver cirrhosis, which in turn causes portal hypertension and varices. <sup>2</sup> Alternative endoscopic modalities have been developed for the investigation of the upper gastrointestinal (GI) tract, such as oesophageal capsule endoscopy (OCE). However, OCE is widely accepted and its indications are still under evaluation. <sup>3</sup> Our aim was to evaluate the use of OCE in a tertiary referral centre for GI problems in Lothian, Southeast Scotland, giving a special focus on OCE in haemophiliacs. <h3>Methods</h3> A retrospective review of the OCE database from May 2005 to March 2012. Electronic case notes and OCE reports were reviewed. Demographics and clinical background, in particular haemophilia, hepatitis C, HIV and cirrhosis, reason for referral and OCE findings were abstracted. <h3>Results</h3> A total of 65 OCEs (50 patients; 27 M/23 F; mean age: 52.7 ± 13.7 years) were carried out in the aforementioned period. 32% pts had haemophilia (16/50 patients/all male; mean age: 51.6 ± 9.8 years; range 31–78 years; 28 OCEs); 5 pts had repeat OCEs (1 pt: 1 repeat, 2 pts: 2 repeat, 1 pt: 3 repeat &amp; 1 patient: 4 repeat OCEs). All haemophiliacs were infected with HCV; 2 pts were co-infected with HIV. 3/16 (18.75%) of haemophiliacs had established cirrhosis, 5/16 (31.25%) probable cirrhosis. In haemophiliacs, indications for OCE were: variceal surveillance (OCEs group A: 17/28; 60.7%) and/or other upper GI symptoms (OCEs group B: 11/28; 39.3%). PillCam®ESO1 was used in 15/28 (53.6%) occasions and PillCam®ESO2 for the rest (13/28; 46.4%). The overall diagnostic yield (DY) of OCE in haemophiliacs was 78% (21/28). The DY was similar in OCEs group A: 64.7% (findings in 11/17) and OCEs group B: 54.5% (findings in 6/11 ), <i>P</i> = 1.0. Oesophageal transit times were mean: 166s; range: 3–1171s. All capsules reached the stomach, but only 8/28 (28.5%) capsules entered the duodenum. <h3>Conclusion</h3> OCE is a useful and acceptable alternative to conventional endoscopy in selected groups of patients. In particular, OCE in haemophiliacs has a high DY and should be considered a first line investigation to guide further endoscopic intervention. <h3>Disclosure of Interest</h3> None Declared. <h3>References</h3> Meijer K,<i> et a</i>l. HCV-related liver cancer in people with haemophilia. Haemophilia 2012; 18:17–24 de Franchis R. Non-invasive (and minimally invasive) diagnosis of oesophageal varices. J Hepatol 2008; 49:520–7 Guturu P<i>, et al</i>. Capsule endoscopy with PILLCAM ESO for detecting esophageal varices: a meta-analysis. Minerva Gastroenterol Dietol 2011; 57:1–11
ADENOMAS DUODENALES ESPORÁDICOS: CARACTERÍSTICAS EPIDEMIOLÓGICAS Y ENDOSCÓPICAS EN UNA SERIE HOSPITALARIA
Authors: F Mesonero, C Teruel, S Parejo, J Martínez-González, M Maroto, C García-Sánchez, FJ García-Alonso, JA González-Martín, D Boixeda de Miquel
Journal: Endoscopy (2011)

Introducción: Los adenomas duodenales esporádicos (AD) son infrecuentes, paucisintomáticos y la mayoría incidentales. Destacan por su potencial maligno y asociación a patología colorrectal.
Effects of Salmeterol on Arterial Blood Gases in Patients with Stable Chronic Obstructive Pulmonary Disease
Authors: GHASSAN KHOUKAZ, NICHOLAS J. GROSS
Journal: American Journal of Respiratory and Critical Care Medicine (1999)

Administration of beta-adrenergic agonist bronchodilators to patients with airways obstruction commonly results in transient decreases in Pa(O(2)) levels despite bronchodilation, an effect that has been attributed to these drugs' pulmonary vasodilator action. We compared the acute effects on gas exchange of salmeterol with those of albuterol and the anticholinergic agent ipratropium in 20 patients with stable chronic obstructive pulmonary disease (COPD). Each agent was given in recommended dosage on separate days in a double-blind, crossover format, and the patients' arterial blood gases (ABGs) were measured at baseline and at intervals to 120 min. Small but statistically significant declines in Pa(O(2)), the primary outcome variable, were found after administration of both salmeterol and albuterol. The decline in PaO2 after salmeterol was of lesser magnitude but was more prolonged than that after albuterol, the greatest mean change being -2.74 +/- 0.89 mm Hg (mean +/- SEM) at 30 min after salmeterol, and -3.45 +/- 0.92 mm Hg at 20 min after albuterol. Following ipratropium, the corresponding change was -1.32 +/- 0.85 mm Hg at 20 min. These declines, which were almost entirely attributable to increases in the alveolar-arterial difference in oxygen tension Delta(A-a)DO2 tended to be more marked in subjects with higher baseline PaO2 values. No subject experienced a decline in PaO2 to levels below 59 mm Hg. There were no significant differences among the three drugs studied. We conclude that despite small decreases in PaO2 after each of the three drugs, the declines were small transient, and of doubtful clinical significance.
Abstract 194: Loss of imprinting and abnormal expression of insulin-like growth factor II in gastric cancer
Authors: Teng Chen, Qin-Song Zuo, Ronghua Zhao, Dian-Xu Feng, Chao Chen, Yi-Min Jiang, Marcia Cruz-Correa, Alan G. Casson, Feng Han
Journal: Cancer Research (2010)

Abstract Introduction: Gastric carcinoma (GC) is a leading cause of cancer mortality worldwide, and is highly prevalent in China. Loss of imprinting (LOI) of insulin-like growth factor II (IGF-2) gene is an important epigenetic phenomenon related to carcinogenesis and tumor progression in many human cancers. To date, however, few studies have evaluated the IGF-2 LOI in GC. Aims: This study aimed: (1) to examine the prevalence of LOI of IGF-2 in tumor, matched normal gastric mucosa, and peripheral blood lymphocyte (PBL) from a well characterized series of patients with GC, and in PBL from a control group, (2) To examine the association of LOI of IGF-2 with circulating IGF-2 and tissue IGF-2 expression. Methods: IGF-2 genomic imprinting status was analyzed by PCR and RT-PCR followed by restrictive endonuclease (Apa I) digestion. Prevalence of LOI in PBL from 33 Apa I informative GC patients (21 males, age: 59.91±13.87) was compared with that from 21 informative controls (13 males, age: 56.81±13.28). Findings were also associated with the clinicopathologic parameters in patients with GC. IGF-2 level in peripheral blood (ng/ml) and tumor were determined with ELISA and immunohistochemical staining, respectively. Results: LOI of IGF-2 was positive in 48.48% (16/33) GC tumor, 21.21% (7/33) adjacent mucosa (AM), 12.12% (4/33) distant mucosa (DM), and 15.15% (5/33) PBL. The prevalence of LOI in PBL was not significantly different between GC patients (5/33, 15.15%) and controls (2/21, 9.52%) (p=0.693). Patients with LOI-positive tumor were more likely to be advanced stage (93.75% vs. 58.82%, p=0.039) or have positive lymph nodes (87.50% vs. 52.94%, p=0.057). Significantly increased blood IGF-2 level was seen in GC patients with LOI-positive tumor (808.07±255.25) when compared with those with LOI-negative tumor (396.21±198.94) (p&amp;lt;0.01). The positive rate of IGF-2 staining was significantly higher in tumor (10 of 16, 62.50%), AM (7 of 7, 100.00%), and DM (3 of 4, 75.00%) with LOI than that in tissues without LOI (tumor: 2 of 17, 11.76%; AM: 2 of 26, 7.69%; DM: 2 of 29, 6.90%) (p&amp;lt;0.01). Conclusions: The results of this study suggest that IGF-2 is a critical factor in carcinogenesis and progression of GC, with LOI of IGF-2 modulating tissue and circulating expression of IGF-2. IGF-2 LOI may represent a potential epigenetic marker for gastric cancer risk, prognosis and treatment stratification. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 194.
White, gray, and black domains of cultural adaptations to climato-economic conditions
Authors: Evert Van de Vliert
Journal: Behavioral and Brain Sciences (2013)

Abstract Forty-nine commentators have reviewed the theory that needs-based stresses and freedoms are shaped differently in threatening, comforting, and challenging climato-economic habitats. Their commentaries cover the white domain, where the theory does apply (e.g., happiness, collectivism, and democracy), the gray domain, where it may or may not apply (e.g., personality traits and creativity), and the black domain, where it does not apply (e.g., human intelligence and gendered culture). This response article provides clarifications, recommendations, and expectations.
Abstract 1841: Selective inhibitors of nuclear export (SINE) activate multiple tumor suppressor pathways and kill prostate cancer cells across multiple genotypes <i>in vitro</i> and <i>in vivo</i>
Authors: Giovanni Luca Gravina, Enrico Ricevuto, Andrea Mancini, Sharon Shechter, Vincent Sandanayaka, Michael G. Kauffman, Sharon Shacham, Claudio Festuccia
Journal: Cancer Research (2012)

Abstract CRM1 (Xpo1) is a key nuclear export protein which controls the nuclear export of multiple tumor suppressor proteins (TSP) and cell proliferation pathways including p53, p21, FOXO, PI3K/AKT, Wnt/ß-catenin and NF-κB. Mislocalization of TSP can abrogate their functions as well as render chemotherapies ineffective. Induction of nuclear expression of TSP and chemotherapy targets, by CRM1 inhibition can restore their tumor suppressor functions and increase drug sensitivity. We have developed orally active, small molecule SINE that irreversibly and potently inhibit CRM1 mediated nuclear export of multiple TSP and other cargoes (IC50 &amp;lt; 100 nM). Here, we describe in vitro results using SINE compounds, KPT-185 in vitro and KPT-251 in vitro and in vivo on seven prostate cancer (PrCa) cell lines representing distinct differentiation/progression states of disease and genotypes: LAPC-4 (Androgen receptor [AR] positive, androgen dependent with low Akt/mTOR activities, p53 wt); LnCaP (AR positive, androgen dependent with high Akt/mTOR activities, p53 wt); LnCaP-C81 and LnCaP-C4-2B (AR positive, androgen independent with high Akt/mTOR activities, p53 wt); 22rv1 (AR positive, androgen independent with low Akt/mTOR activities, p53 wt); PC3 (AR negative, with high Akt/mTOR activites and no p53 function (p53 del) and DU145 (AR negative, with low Akt/mTOR activites and mutant p53). Benign prostatic hyperplasia line (BPH1) and Prostatic epithelial line (EPN) were used as non-neoplastic controls. We show that SINE block CRM1 mediated nuclear export of FOXO and p53 with a IC50 values &amp;lt;100 nM in both PrCa and non-neoplastic cell lines. KPT compounds are selectively cytotoxic to PrCa lines with EC50s between 10 and 1000 nM, and show limited cytotoxicity on the non-neoplastic EPN and BPH1 lines (EC50 &amp;gt;5-20 μM). SINE cytotoxic effects are independent of p53 status, and induce caspase-3 activation. SINE display synergistic effects in combination with cisplatin and docetaxel in vitro with combination indices between 0.3 and 0.8. In vivo results indicate that KPT-251 show a dose-dependent inhibition of tumor growth. KPT251 was also synergistic when administered at 30mg/kg/5 days/week per os with docetaxel and cisplatin by using the aggressive p53 wt 22rv1 xenografts. Taken together, CRM1 inhibition represents a completely novel, neoplasia-selective and well- tolerated target for use as single agent or in combination with chemotherapy for PrCa. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1841. doi:1538-7445.AM2012-1841